KARL-DIMITER BISSIG to Hepatitis B virus
This is a "connection" page, showing publications KARL-DIMITER BISSIG has written about Hepatitis B virus.
Connection Strength
1.201
-
HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018 05; 20(5):697-705.
Score: 0.557
-
Hepatitis B Virus HBx Protein Mediates the Degradation of Host Restriction Factors through the Cullin 4 DDB1 E3 Ubiquitin Ligase Complex. Cells. 2020 03 30; 9(4).
Score: 0.160
-
Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Curr HIV Res. 2020; 18(1):19-28.
Score: 0.157
-
CRISPR/Cas9: at the cutting edge of hepatology. Gut. 2017 07; 66(7):1329-1340.
Score: 0.131
-
Combinatorial RNA Interference Therapy Prevents Selection of Pre-existing HBV Variants in Human Liver Chimeric Mice. Sci Rep. 2015 Oct 20; 5:15259.
Score: 0.117
-
Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J Clin Invest. 2010 Mar; 120(3):924-30.
Score: 0.079